| Literature DB >> 32037504 |
Andrea Denegri1, Valentina A Rossi2, Fabrizio Vaghi3, Paolo Di Muro3, Martino Regazzi3, Tiziano Moccetti3, Elena Pasotti3, Giovanni B Pedrazzini3, Mauro Capoferri3, Marco Moccetti3.
Abstract
BACKGROUND: Cardiac rehabilitation (CR) is strongly associated with all-cause mortality reduction in patients with coronary artery disease (CAD). The impact of CR on pathological risk factors, such as impaired glucose tolerance (IGT) and functional recovery remains under debate. The aim of the present study is to determine whether CR had a positive effect beside physical exercise improvement on pathological risk factors in IGT and diabetic patients with CAD.Entities:
Keywords: cardiac rehabilitation; cardiopulmonary test; coronary artery disease; diabetes mellitus; reduced glucose tolerance
Mesh:
Substances:
Year: 2020 PMID: 32037504 PMCID: PMC8890425 DOI: 10.5603/CJ.a2020.0006
Source DB: PubMed Journal: Cardiol J ISSN: 1898-018X Impact factor: 2.737
Main characteristics of cardiac rehabilitation (CR) patients according to glycemic status.
| Euglycemic (glycemic < 5.6 mmol/L) (n = 88) | IGT (glycemic 5.6–7.0 mmol/L) (n = 59) | Diabetics (glycemic > 7.0 mmol/L) (n = 24) | |
|---|---|---|---|
| Age | 60,45 | 63,35 | 69,30 |
| Male | 53 | 66 | 24 |
| Familial history of CHD | 25 | 23 | 4 |
| Hypertension | 32 | 42 | 20 |
| Dyslipidemia | 36 | 40 | 11 |
| Diabetes | 1 | 12 | 21 |
| Smoking | 35 | 38 | 6 |
| Statin therapy | 56 | 61 | 21 |
| ACEI | 40 | 41 | 19 |
| Beta-blockers | 59 | 68 | 17 |
| Acetylsalicylic acid | 64 | 68 | 24 |
| Stable angina | 28 | 20 | 9 |
| Unstable angina | 3 | 2 | 0 |
| NSTEMI | 18 | 4 | 4 |
| STEMI | 25 | 22 | 9 |
| PTCA | 55 | 40 | 13 |
| CABG (also previous) | 23 | 12 | 12 |
| Waist > 88 or > 102 cm | 31 | 33 | 17 |
| Weight > 60 or > 70 kg | 50 | 66 | 23 |
| ΔGlucose | −0.16 ± 0.46 (p = 0.25) | −0.35 ± 0.75 (p = 0.02) | 0.52 ± 1.40 (p < 0.05) |
| ΔHbA1c | 0.40 ± 0.97 (p = 0.67) | 0.28 ± 0.53 (p = 0.28) | −0.29 ± 1.20 (p = 0.02) |
Data are presented as mean ± standard deviation or percentage. ACEI — angiotensin converting enzyme inhibitor; CABG — coronary artery by-pass graft; CHD — chronic heart disease; HbA1c — glycated hemoglobin; IGT — impaired glucose tolerance; NSTEMI — non-ST-segment elevation myocardial infarction; PTCA — percutaneous transluminal coronary angioplasty; STEMI — ST-segment elevation myocardial infarction
Cardiopulmonary test values pre- and post-cardiac rehabilitation (CR).
| Euglycemic (< 5.6) (n = 63) | IGT (5.6–7.0) (n=66) | Diabetics (> 7.0) (n = 19) | P | |
|---|---|---|---|---|
| Watt pre-CR | 128.5 ± 41.2 | 128.4 ± 40.0 | 104.7 ± 38.2 |
|
| Watt post-CR | 137.4 ± 44.0 | 142.1 ± 46.1 | 116.1 ± 41.3 | 0.08 |
| METs pre-CR | 5.7 ± 1.4 | 5.9 ± 1.9 | 4.8 ± 0.8 |
|
| METs post-CR | 6.6 ± 1.8 | 6.3 ± 1.8 | 4.9 ± 1.4 |
|
| VO2-peak pre-CR | 19.3 ± 5.3 | 20.1 ± 6.3 | 16.9 ± 3.8 | 0.07 |
| VO2-peak post-CR | 22.5 ± 5.9 | 21.5 ± 7.0 | 18.0 ± 4.4 |
|
| VO2 threshold pre-CR | 13.9 ± 4.2 | 14.7 ± 4.3 | 12.3 ± 2.5 | 0.11 |
| VO2 threshold post-CR | 16.0 ± 4.6 | 16.3 ± 4.6 | 13.7 ± 3.9 | 0.05 |
| O2 beat pre-CR | 12.3 ± 3.1 | 13.0 ± 3.5 | 11.6 ± 2.3 | 0.35 |
| O2 beat post-CR | 13.1 ± 3.4 | 13.5 ± 3.7 | 11.9 ± 2.9 | 0.19 |
| Breath reserve pre-CR | 40.8 ± 15.9 | 38.1 ± 15.3 | 37.0 ± 13.5 | 0.33 |
| Breath reserve post-CR | 37.9 ± 17.1 | 37.0 ± 14.9 | 33.4 ± 14.6 | 0.31 |
Data are presented as mean ± standard deviation. Statistical significance is shown for euglycemic patients vs. diabetics. IGT — impaired glucose tolerance; METs — metabolic equivalents; VO2 — oxygen volume
Figure 1Peak workload and VO2-peak improvement; A. Peak workload comparison between euglycemic (blue bars), impaired glucose tolerance (IGT; yellow bars) and diabetic patients (red bars); B. VO2-peak comparison between euglycemic (blue bars), IGT (yellow bars) and diabetic patients (red bars); NS — not significant.
Figure 2Linear regression, showing an inverse correlation between fasting glucose and VO2-peak improvement, suggesting that response to cardiac rehabilitation may be impaired by poor glycemic control.